Veoneer Inc (VNE) Fundamental Analysis & Valuation

NYSE:VNE

Current stock price

36.95
+0.07 (+0.19%)
At close:
36.96
+0.01 (+0.03%)
After Hours:

This VNE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. VNE Profitability Analysis

1.1 Basic Checks

  • In the past year VNE has reported negative net income.
VNE Yearly Net Income VS EBIT VS OCF VS FCFVNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -100M -200M -300M -400M -500M

1.2 Ratios

Industry RankSector Rank
ROA -22%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VNE Yearly ROA, ROE, ROICVNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 -10 -20 -30 -40

1.3 Margins

Industry RankSector Rank
OM -20.46%
PM (TTM) -23.23%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VNE Yearly Profit, Operating, Gross MarginsVNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 10 -10 20 -20 -30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. VNE Health Analysis

2.1 Basic Checks

  • VNE has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for VNE has been reduced compared to a year ago.
VNE Yearly Shares OutstandingVNE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M
VNE Yearly Total Debt VS Total AssetsVNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • VNE has an Altman-Z score of 2.01. This is not the best score and indicates that VNE is in the grey zone with still only limited risk for bankruptcy at the moment.
  • A Debt/Equity ratio of 0.27 indicates that VNE is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z 2.01
ROIC/WACCN/A
WACCN/A
VNE Yearly LT Debt VS Equity VS FCFVNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 500M -500M 1B 1.5B

2.3 Liquidity

  • VNE has a Current Ratio of 1.67. This is a normal value and indicates that VNE is financially healthy and should not expect problems in meeting its short term obligations.
  • VNE has a Quick Ratio of 1.33. This is a normal value and indicates that VNE is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.67
Quick Ratio 1.33
VNE Yearly Current Assets VS Current LiabilitesVNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. VNE Growth Analysis

3.1 Past

  • VNE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.05%, which is quite impressive.
  • Looking at the last year, VNE shows a very strong growth in Revenue. The Revenue has grown by 20.77%.
  • Measured over the past years, VNE shows a decrease in Revenue. The Revenue has been decreasing by -5.67% on average per year.
EPS 1Y (TTM)20.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.1%
Revenue 1Y (TTM)20.77%
Revenue growth 3Y-9.4%
Revenue growth 5Y-5.67%
Sales Q2Q%-1.32%

3.2 Future

  • Based on estimates for the next years, VNE will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.01% on average per year.
  • VNE is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.15% yearly.
EPS Next Y45.31%
EPS Next 2Y32.27%
EPS Next 3Y27.67%
EPS Next 5Y15.01%
Revenue Next Year26.64%
Revenue Next 2Y22.93%
Revenue Next 3Y19.71%
Revenue Next 5Y18.15%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VNE Yearly Revenue VS EstimatesVNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1B 2B 3B
VNE Yearly EPS VS EstimatesVNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -1 -2 -3 -4 -5

More info and screens

Find the best growth stocksShow best growing peers

1

4. VNE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VNE. In the last year negative earnings were reported.
  • Also next year VNE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VNE Price Earnings VS Forward Price EarningsVNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -17.53
VNE Per share dataVNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • VNE's earnings are expected to grow with 27.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.27%
EPS Next 3Y27.67%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VNE Dividend Analysis

5.1 Amount

  • No dividends for VNE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

VNE Fundamentals: All Metrics, Ratios and Statistics

Veoneer Inc

NYSE:VNE (3/31/2022, 8:04:26 PM)

After market: 36.96 +0.01 (+0.03%)

36.95

+0.07 (+0.19%)

Chartmill FA Rating
GICS IndustryGroupAutomobiles & Components
GICS IndustryAutomobile Components
Earnings (Last)02-02
Earnings (Next)04-27
Inst Owners1.11%
Inst Owner Change0%
Ins Owners0.04%
Ins Owner Change0%
Market Cap4.14B
Revenue(TTM)1.66B
Net Income(TTM)-385.00M
Analysts54
Price Target34 (-7.98%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.5
P/FCF N/A
P/OCF N/A
P/B 4.85
P/tB N/A
EV/EBITDA -17.53
EPS(TTM)-3.43
EYN/A
EPS(NY)-1.88
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS14.79
BVpS7.61
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -22%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -20.46%
PM (TTM) -23.23%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.67
Quick Ratio 1.33
Altman-Z 2.01
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.1%
EPS Next Y45.31%
EPS Next 2Y32.27%
EPS Next 3Y27.67%
EPS Next 5Y15.01%
Revenue 1Y (TTM)20.77%
Revenue growth 3Y-9.4%
Revenue growth 5Y-5.67%
Sales Q2Q%-1.32%
Revenue Next Year26.64%
Revenue Next 2Y22.93%
Revenue Next 3Y19.71%
Revenue Next 5Y18.15%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Veoneer Inc / VNE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of Veoneer Inc (VNE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to VNE.


What is the valuation status for VNE stock?

ChartMill assigns a valuation rating of 1 / 10 to Veoneer Inc (VNE). This can be considered as Overvalued.


Can you provide the profitability details for Veoneer Inc?

Veoneer Inc (VNE) has a profitability rating of 1 / 10.